Zobrazeno 1 - 10
of 1 319
pro vyhledávání: '"Smolen, JS"'
Autor:
Menzies-Gow AN, Tran TN, Stanley B, Carter VA, Smolen JS, Bourdin A, Fitzgerald JM, Raine T, Chapaneri J, Emmanuel B, Jackson DJ, Price DB
Publikováno v:
Pragmatic and Observational Research, Vol Volume 15, Pp 53-64 (2024)
Andrew N Menzies-Gow,1,2 Trung N Tran,3 Brooklyn Stanley,4 Victoria Ann Carter,4 Josef S Smolen,5 Arnaud Bourdin,6 J Mark Fitzgerald7 ,† Tim Raine,8 Jatin Chapaneri,2 Benjamin Emmanuel,3 David J Jackson,9,10 David B Price4,11 1Royal Brompton and Ha
Externí odkaz:
https://doaj.org/article/c8bba9095db94408977af49602539026
Autor:
Mease, PJ, Gladman, DD, Ogdie, A, Coates, LC, Behrens, F, Kavanaugh, A, Mcinnes, I, Queiro, R, Guerette, B, Brunori, M, Teng, L, Smolen, JS
Objective: To evaluate the probability of achieving Clinical Disease Activity for Psoriatic Arthritis (cDAPSA) treatment targets of remission (REM) or low disease activity (LDA) with apremilast based on disease activity categories and corresponding r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::4a79355d4a515e471d2994d8712e5673
https://doi.org/10.1002/acr.24134
https://doi.org/10.1002/acr.24134
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-2 (2020)
Arthritis Research & Therapy
Arthritis Research & Therapy
Background In clinical practice, temporary interruption of rheumatoid arthritis (RA) therapy is common for various reasons including side effects, non-compliance, or necessity for surgery. To characterize temporary interruptions of baricitinib and pl
Background Biologic disease-modifying antirheumatic drugs (bDMARDs) are important options for managing rheumatoid arthritis (RA). Once patients achieve disease control, clinicians may consider dose reduction or withdrawal of the bDMARD. Results from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::5c7b59b43f23d8bdd8563a47983e1e25
https://eprints.whiterose.ac.uk/147031/3/s13075-019-1937-4.pdf
https://eprints.whiterose.ac.uk/147031/3/s13075-019-1937-4.pdf
Autor:
Emery, P, Suh, C-H, Weinblatt, ME, Smolen, JS, Keystone, EC, Genovese, M, Vencovsky, J, Kay, J, Hong, E, Baek, Y, Ghil, J, Weinblatt, M E, Smolen, J S, Keystone, E C
Publikováno v:
Scandinavian Journal of Rheumatology; Sep2020, Vol. 49 Issue 5, p361-370, 10p
Autor:
Charles, P, Elliott, MJ, Davis, D, Potter, A, Kalden, JR, Antoni, C, Breedveld, FC, Smolen, JS, Eberl, G, deWoody, K, Feldmann, M, Maini, RN
Treatment with a chimeric mAb to TNF-alpha has been shown to suppress inflammation and improve patient well-being in rheumatoid arthritis (RA), but the mechanisms of action of such treatment have not been fully explored. Here we show that in vivo adm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::523c29df7f3ae05c66467d7446fe9649
https://ora.ox.ac.uk/objects/uuid:2f6276f0-3066-4752-997f-b334aaafcaaa
https://ora.ox.ac.uk/objects/uuid:2f6276f0-3066-4752-997f-b334aaafcaaa
Autor:
Walker U. A., Tyndall A., Czirják L, Denton C. ., Farge Bancel D., Kowal Bielecka O., Müller Ladner U., Bocelli Tyndall C., Matucci Cerinic M., Riemekasten G. ., Brückner C. ., Airó P. ., Scarsi M. ., Scorza R. ., Beretta L. ., Cozzi F. ., Tiso F., Vonk Mc M. C., Hoogen Van Den, Fhj F. H. J., Wigley Fm F. M., Hummers L. ., Nevskaya T. ., Ananieva L. ., Miniati I. ., Tartaglia N. ., Lomater C. ., Balbir Gurman A. ., Braun Moscovici Y. ., Bambara Lm L. M., Caramaschi P. ., Ruocco L. ., Krieg T. ., Hunzelmann N. ., Varjú C. ., Carriera Pe P. E., Joven B. ., Iannone F. ., Lapadula G. ., Kahan A. ., Allanore Y. ., Gabrielli A. ., Imperatore M. ., Scheja A. ., Wollheim F. ., Damjanov N. ., Ostojic P. ., Saar P. ., Tarner Ih I. H., Kötter I. ., Bombardieri S. ., Bazzichi L. ., Papa Del N. ., Comina Dp D. P., Monaco Lo A. ., Corte La R. ., Hachulla E. ., Launay D. ., Distler O. ., Ciurea A. ., Sierakowski S. ., Mitchell H. ., Silver Rm R. M., Krasowska D. ., Michalska Jakubus M. ., Tikly M. ., Aboo N. ., Worm M. ., Klaus P. ., Rovenský J. ., Lukáčová O. ., Rozman B. ., Sipek A. ., Clemente Coelho P. ., Shoenfeld Y. ., Langewitch P. ., José Da Silva Ap A. P., Salvador Mj M. J., Kuhn A. ., Erdmann G. ., Bečvář R. ., Friedl E. ., Graninger W. ., Riccieri V. ., Caporali R. ., Montecucco C. ., Vlachoyiannopoulos P. ., Distler M. ., Reich K. ., Majdan M. ., Wielosz E. ., Rednic S. ., Laar Van Jm J. M., Heitmann S. ., Bruckner A. ., Himsel A. ., Riemann J. ., Meyringer R. ., Müller A. ., Martinovic D. ., Radic M. ., Sticherling M. ., Szekanecz Z. ., Szücs G. ., Giacomelli R. ., Marrelli A. ., Stamenkovic B. ., Stankovic A. ., Aringer M. ., Smolen Js J. S., Kucharz Ej E. J., Kotulska At A. T., Jablonska S. ., Blasczik M. ., Jun J. B. J. B., Mallia C. ., Coleiro B. ., Santamaria Vo V. O., Hinrichs R. ., Nielsen H. ., Cossutta R. ., Ionescu R. ., Opris D. ., Steinbrink K. ., Grundt B. ., Bajocchi G. ., Jiří Š. ., Lefebvre Pgdlp P. G. D. L. P., Mendoza ZeaAc A. C., Ribi C. ., Chizzolini C. ., Wisłowska M. ., Novak S. ., Indiveri F. ., Jacobsen S. ., Frandsen Pb P. B., Gorska Iz I. Z., Gran Tore J. ., Midtvedt Ø. ., Ramos Fo F. O., Rajcevska Ld L. D., Bozinovski G. ., Schöffel D. ., Sunderkötter C. ., Böhm M. ., Morović Vergles J. ., Čulo M. I. M. I., Cutolo M. ., Sulli A. ., Derk Ct C. T., Jimenez Sa S. A., Siakka P. ., Søndergaard K. ., Stengaard Pedersen K. ., Cabane J. ., Tiev Kp K. P., Mihai C. ., Sfrent Cornateanu R. ., Jendro M. ., Tuvik P. ., Antivalle M. ., Randisi G. ., Seidel M. ., Clarenbach R. ., Simsek I. ., Dinc A. ., Inanc M. ., Capraru Ms M. S., Capraru D. ., Bañegil I. ., Richter J. ., Alhasani S. ., Földvari I. ., Pinto S. ., Brandão F. ., VALENTINI, Gabriele
Publikováno v:
Annals of the Rheumatic Diseases, Vol. 66, No 6 (2007) pp. 754-63
Background: Systemic sclerosis (SSc) is a multisystem autoimmune disease which is classified into a diffuse cutaneous (dcSSc) and a limited cutaneous (lcSSc) subset according to the skin involvement. In order to better understand the vascular, immuno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eb0c0431aa5a4b9c2f8a8fe0cb79a53
Autor:
Schoels, Mm, Van Der Heijde, D, Breedveld, Fc, Burmester, Gr, Dougados, M, Emery, P, Ferraccioli, Gianfranco, Gabay, C, Gibofsky, A, Gomez Reino, Jj, Jones, G, Kvien, Tk, Murakami, M, Murikama, Mm, Nishimoto, N, Smolen, Js
Publikováno v:
Annals of the Rheumatic Diseases, 72(4), 583-589
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, Vol. 72, No 4 (2013) pp. 583-9
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, Vol. 72, No 4 (2013) pp. 583-9
Background Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid art
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dcd89f6b6a3c70daee2561a6377538e
https://hdl.handle.net/1887/98414
https://hdl.handle.net/1887/98414
Autor:
Mosca, M, Tani, C, Talarico, R, Aringer, M, Bombardieri, S, Boumpas, D, Brey, R, Cervera, R, Doria, A, Jayne, D, Khamashta, Ma, Kuhn, A, Gordon, C, Petri, M, Rekvig, Op, Schneider, M, Sherer, Y, Shoenfeld, Y, Smolen, Js, Tincani, Angela, van Vollenhoven RF, Ward, Mm, Werth, Vp, Carmona, L.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3662::4717b961ee8139e1e39967baeaac7bcd
http://hdl.handle.net/11379/80687
http://hdl.handle.net/11379/80687